Firetrail Investments becomes substantial holder in PYC Therapeutics

Firetrail Investments Pty Ltd became a substantial holder in PYC Therapeutics Ltd on November 5, 2025. The investment firm now holds a relevant interest in 29,493,423 ordinary fully paid shares, representing a 5.06% voting power in the company.

The securities are registered across several nominee companies, with BNP Paribas Nominees Pty Limited holding 5,977,696 shares, Citicorp Nominees Pty Limited holding 14,594,730 shares, and Northern Trust holding 8,920,997 shares. Firetrail Investments Pty Ltd, in its capacity as an investment manager, controls the voting and disposal power of these securities.

The acquisition of these shares involved numerous purchase and sale transactions between July 8, 2025, and November 5, 2025. Significant purchases include transactions on July 11, 2025, for A$2,937,024.00, and on October 13, 2025, for A$1,276,511.89. The most recent acquisition activity on November 5, 2025, involved purchases totalling A$1,497,002.81 and sales of A$752,028.48.